Ascentage Pharma Announces Purchase of 50,000 Shares by Trustee for 2022 RSU Scheme

On May 28, 2026, Ascentage Pharma Group International announced that the Trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 50,000 existing shares on-market. The purchase was conducted to satisfy the vesting requirements of RSUs granted under the scheme. The shares were acquired at an average price of approximately HK$38.196 per share, totaling a consideration of HK$1,909,800 (excluding transaction costs). Following this transaction, the total number of existing shares purchased by the Trustee for the 2022 RSU Scheme reached 2,315,000 shares. The purchased shares represent approximately 0.0134% of the company's total issued shares as of the announcement date. These shares are held in trust according to the scheme rules, and the Trustee is prohibited from exercising voting rights associated with them. This purchase follows a series of similar transactions and RSU grants previously disclosed by the company between 2022 and 2026. No new awards were granted in conjunction with this specific share purchase announcement.